Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Richard Segiel, Jr. Joins Almac as Vice President of US Business Development

Published: Wednesday, October 30, 2013
Last Updated: Wednesday, October 30, 2013
Bookmark and Share
Richard will focus on developing new business, maintaining existing business, and developing partnerships.

Almac’s Clinical Services Business Unit has announced that Richard Segiel, Jr. has joined the company as Vice President of Business Development for the United States. He brings with him 23 successful years of experience in the contract pharmaceutical development sector. In his new role, he will focus on developing new business, maintaining existing business, and developing partnerships.

Prior to joining Almac, Richard held a number of Business Development and Operational positions at Intertek Pharmaceutical Services, MDS Tricon, Celsis Analytical Services, and Pharmakon Research International.

“Richard brings a compelling mix of business development, operational, and financial experience that will further strengthen Almac's leadership team. This skill set is key to delivering on our core objective of enhancing our US client relationships, further developing our commitment to customer service, and helping achieve true strategic partnerships,” said Martin Lamb, Global VP of Business Development.

Most recently, Richard served as Business Development Director of Intertek Pharmaceutical Services where he had direct responsibility for all Business Development and Sales initiatives for the company’s Chemical and Pharmaceutical Division NA.

As Vice President, Business Development at Celsis Analytical Services, Richard assembled the sales and client services divisions, which achieved record sales performance for six consecutive years under his supervision.

Additionally, Richard implemented many sales infrastructure programs including the organization’s first CRM system, new KPI metrics, as well as successful sales compensation plans.

“We are very pleased to have Richard on our growing Business Development team. Richard’s experience in the contract pharmaceutical development sector coupled with his proven ability to develop, build, and manage a world-class sales force will make him a vital asset to our team,” says Robert Dunlop, President of Almac’s Clinical Services Business Unit. “Our goal was to find a proven leader who could help us grow our business in the US, and Richard is the perfect fit.”

Richard holds a bachelor’s degree in Chemistry and Business from the University of Scranton and an MBA in Marketing and Finance. Richard lives in Gouldsboro, Pennsylvania with his wife Kimarie and their two children.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac Wins Laboratory Team of the Year at The Irish Laboratory Awards 2013
The awards held to recognize the success and achievements of Ireland’s internationally renowned scientists.
Thursday, December 12, 2013
Almac Secures New Metagenomics and Enzyme Discovery Programme with UCL
The BBRSC Programme combines Chemistry and Biochemical Engineering at UCL with Almac’s Biocatalysis Group.
Wednesday, May 15, 2013
Todd Kole Appointed to Almac’s Clinical Technologies Executive Team
Todd will oversee clinical project management and drug supply services globally.
Tuesday, August 30, 2011
Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!